Cerity Partners LLC Boosts Stake in Omnicell, Inc. (NASDAQ:OMCL)

Cerity Partners LLC raised its position in shares of Omnicell, Inc. (NASDAQ:OMCLGet Rating) by 13.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,925 shares of the company’s stock after acquiring an additional 235 shares during the period. Cerity Partners LLC’s holdings in Omnicell were worth $219,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Inspire Investing LLC grew its position in Omnicell by 2.3% during the second quarter. Inspire Investing LLC now owns 7,677 shares of the company’s stock valued at $873,000 after acquiring an additional 170 shares during the period. WINTON GROUP Ltd grew its position in Omnicell by 32.9% during the second quarter. WINTON GROUP Ltd now owns 13,741 shares of the company’s stock valued at $1,563,000 after acquiring an additional 3,403 shares during the period. Swiss National Bank grew its position in Omnicell by 0.8% during the second quarter. Swiss National Bank now owns 104,700 shares of the company’s stock valued at $11,910,000 after acquiring an additional 800 shares during the period. Lazard Asset Management LLC grew its position in Omnicell by 1,045.9% during the second quarter. Lazard Asset Management LLC now owns 884,541 shares of the company’s stock valued at $100,616,000 after acquiring an additional 807,348 shares during the period. Finally, Shell Asset Management Co. grew its position in Omnicell by 5.7% during the second quarter. Shell Asset Management Co. now owns 7,269 shares of the company’s stock valued at $827,000 after acquiring an additional 395 shares during the period.

Insider Buying and Selling at Omnicell

In other Omnicell news, CFO Peter J. Kuipers sold 15,500 shares of the company’s stock in a transaction that occurred on Friday, August 26th. The stock was sold at an average price of $108.29, for a total transaction of $1,678,495.00. Following the sale, the chief financial officer now owns 61,326 shares in the company, valued at $6,640,992.54. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 2.76% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on OMCL shares. KeyCorp lowered their price target on Omnicell from $130.00 to $75.00 and set an “overweight” rating for the company in a research report on Thursday, November 3rd. Piper Sandler reduced their price objective on Omnicell from $145.00 to $58.00 in a research note on Wednesday, November 2nd. SVB Leerink reduced their price objective on Omnicell from $117.00 to $54.00 and set a “market perform” rating on the stock in a research note on Thursday, November 3rd. JPMorgan Chase & Co. reduced their price objective on Omnicell from $140.00 to $57.00 and set a “neutral” rating on the stock in a research note on Friday, November 18th. Finally, Wells Fargo & Company reduced their price objective on Omnicell from $158.00 to $71.00 and set an “overweight” rating on the stock in a research note on Friday, November 4th. Four analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, Omnicell has an average rating of “Moderate Buy” and an average price target of $82.44.

Omnicell Trading Up 0.2 %

NASDAQ:OMCL opened at $52.28 on Wednesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.86 and a current ratio of 2.25. Omnicell, Inc. has a one year low of $46.19 and a one year high of $185.28. The business’s 50-day simple moving average is $73.57 and its 200 day simple moving average is $97.34. The stock has a market cap of $2.32 billion, a price-to-earnings ratio of 51.26, a price-to-earnings-growth ratio of 1.71 and a beta of 1.01.

About Omnicell

(Get Rating)

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

Featured Stories

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCLGet Rating).

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.